Granted Patent B2

US 12,390,464 · App. 17/641,868 · Granted Aug 19, 2025

Inventors: Michael Nicholas Greco (Lansdale, PA); Michael John Costanzo (Bonney Lake, WA); Michael Alan Green (Easton, PA); Don Zhang (Princeton, NJ); Jirong Peng (Mequon, WI)

Assignee: BETA PHARMA, INC.

A61K31/506A61P11/00A61P35/00

Abstract

Claims (117)

1. A method of treating a cancer associated with a mutant of epidermal growth factor receptor (EGFR) in a subject, the method comprising administering to the subject a therapeutically effective amount of an EGFR inhibitor of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in combination with a synergistically effective amount of cyclin-dependent kinase (CDK) inhibitor of formula (II), or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein the synergistically effective amount formula (II) comprises approximately 6.25 to 100 mg/kg of formula (II):

wherein in formula (I):

G is selected from the group consisting of substituted or unsubstituted 1H-indol-3-yl, substituted or unsubstituted 1H-indazol-3-yl, substituted or unsubstituted 2H-indazol-3-yl, and substituted or unsubstituted pyrazolo[1,5-a]-pyridin-3-yl, and substituted or unsubstituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl;

X is oxygen, sulfur, or methylene;

R 1 is hydrogen, halogen, methyl, trifluoromethyl, or cyano;

R 2 , R 3 , and R 4 are the same or different and are independently selected from the group consisting of hydrogen, halogen, and trifluoromethyl;

R 5 is selected from the group consisting of lower alkyl, optionally substituted 3- to 6-membered heterocyclyl, R 7 R 8 N-(lower alkyl), and R 7 R 8 N-(cycloalkylalkyl), wherein R 7 and R 8 are the same or different and are independently selected from hydrogen and lower alkyl; and

R 6 is lower alkoxy or lower alkyl;

and wherein in formula (II):

R a is hydrogen, C 1 -C 8 alkyl, or C 3 -C 7 cycloalkyl;

R b and R c are each independently selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 3 -C 7 cycloalkyl, and C 3 -C 7 cycloalkylmethyl;

R d is hydrogen, halogen, C 1 -C 8 alkyl, or C 3 -C 7 cycloalkyl; and

R e is hydrogen or halogen.

2. The method of claim 1 , wherein R a is C 1 -C 6 alkyl; R b is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or C 3 -C 6 cycloalkylmethyl; and R c is C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl.

3. The method of claim 1 , wherein R a is methyl, ethyl, propyl, or isopropyl; R b is methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclopentyl, cyclopropylmethyl, or cyclopentylmethyl; and R c is methyl, ethyl, propyl, isopropyl, or cyclopropyl.

4. The method of claim 1 , wherein R d is hydrogen or halogen located at the 7-position of the indazole ring, and R e is hydrogen or fluoro, characterized by formula Ia:

5. The method of claim 1 , wherein R a is methyl or ethyl; R b is isopropyl, cyclopropyl, cyclopropylmethyl, or cyclopentyl; and R 4 is hydrogen or fluoro.

6. The method of claim 1 , wherein the compound of formula (II) is selected from the group consisting of:

7. The method of claim 1 , wherein the compound of formula (II) is selected from the list of Table 1 herein

Example

Structure

Name

II-1  (or 2)

N-(5-((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoro-4-(3-isopropyl-2- methyl-2H-indazol-5- yl)pyrimidin-2-amine

II-2 

N-(5-((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoro-4-(7-fluoro-3- isopropyl-2-methyl-2H- indazol-5-yl)pyrimidin-2- amine

II-3 

N-(5-((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-4- (7-fluoro-3-isopropyl-2- methyl-2H-indazol-5- yl)pyrimidin-2-amine

II-4 

4-(3-cyclopentyl-2- methyl-2H-indazol-5-yl)- N-(5-((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-5 

4-(3-cyclopentyl-7-fluoro- 2-methyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-6 

4-(3-cyclopentyl-7-fluoro- 2-methyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-7 

4-(3-cyclopropyl-2- methyl-2H-indazol-5-yl)- N-(5-((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-8 

4-(3-cyclopropyl-7- fluoro-2-methyl-2H- indazol-5-yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-9 

4-(3-cyclohexyl-2-methyl- 2H-indazol-5-yl)-N-(5- ((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-10

4-(3-cyclohexyl-7-fluoro- 2-methyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-11

5-fluoro-4-(3-isopropyl-2- methyl-2H-indazol-5-yl)- N-(5-((4- isopropylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-12

5-fluoro-4-(7-fluoro-3- isopropyl-2-methyl-2H- indazol-5-yl)-N-(5-((4- isopropylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-13

4-(3-cyclopentyl-2- methyl-2H-indazol-5-yl)- 5-fluoro-N-(5-((4- isopropylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-14

4-(3-cyclopentyl-7-fluoro- 2-methyl-2H-indazol-5- yl)-5-fluoro-N-(5-((4- isopropylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-15

5-fluoro-4-(3-isopropyl-2- methyl-2H-indazol-5-yl)- N-(5-((4-propylpiperazin- 1-yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-16

5-fluoro-4-(7-fluoro-3- isopropyl-2-methyl-2H- indazol-5-yl)-N-(5-((4- propylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-17

4-(3-cyclopentyl-2- methyl-2H-indazol-5-yl)- 5-fluoro-N-(5-((4- propylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-18

4-(3-cyclopentyl-7-fluoro- 2-methyl-2H-indazol-5- yl)-5-fluoro-N-(5-((4- propylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-19

4-(3-ethyl-2-methyl-2H- indazol-5-yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-20

4-(3-ethyl-7-fluoro-2- methyl-2H-indazol-5-yl)- N-(5-((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-21

4-(3-(sec-butyl)-2-methyl- 2H-indazol-5-yl)-N-(5- ((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-22

4-(3-(sec-butyl)-7-fluoro- 2-methyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-23

4-(2-ethyl-3-isopropyl- 2H-indazol-5-yl)-N-(5- ((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-24

4-(2-ethyl-7-fluoro-3- isopropyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-25

4-(3-cyclopropyl-2-ethyl- 2H-indazol-5-yl)-N-(5- ((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-26

4-(3-cyclopropyl-2-ethyl- 7-fluoro-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-27

4-(3-(cyclopropylmethyl)- 2-methyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-28

4-(3-(cyclopropylmethyl)- 7-fluoro-2-methyl-2H- indazol-5-yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-29

4-(3-cyclopropyl-2-ethyl- 7-fluoro-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2- yl)pyrimidin-2-amine

II-30

4-(3-(sec-butyl)-2-methyl- 2H-indazol-5-yl)-N-(5- ((4-ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-31

4-(3-(sec-butyl)-7-fluoro- 2-methyl-2H-indazol-5- yl)-N-(5-((4- ethylpiperazin-1- yl)methyl)pyridin-2-yl)-5- fluoropyrimidin-2-amine

II-32

5-fluoro-4-(3-isopropyl-2- methyl-2H-indazol-5-yl)- N-(5-(piperazin-1- ylmethyl)pyridin-2- yl)pyrimidin-2-amine

II-33

5-fluoro-4-(7-fluoro-3- isopropyl-2-methyl-2H- indazol-5-yl)-N-(5- (piperazin-1- ylmethyl)pyridin-2- yl)pyrimidin-2-amine

II-34

4-(7-fluoro-3-isopropyl-2- methyl-2H-indazol-5-yl)- N-(5-(piperazin-1- ylmethyl)pyridin-2- yl)pyrimidin-2-amine.

8. The method of claim 1 , wherein:

G is selected from the group consisting of 1H-indol-3-yl, 1-methyl-1H-indol-3-yl, 1-(2-fluoroethyl)-1H-indol-3-yl, 1,2-dimethyl-1H-indol-3-yl, pyrazolo[1,5-a]-pyridin-3-yl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl, 1-methyl-1H-indazol-3-yl, and 2-methyl-2H-indazol-3-yl; R 1 is hydrogen, halogen, or methyl; R 2 is hydrogen, F, or Cl; R 3 is hydrogen, F, Cl, or —CF 3 ; R 1 is hydrogen or halogen; and R 5 is selected from C 1 -C 6 alkyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, R 7 R 8 N—(CH 2 ) n — (n=1 to 5), R 7 R 8 N—(C 3 -C 6 cycloalkyl)-(CH 2 ) m — (m=1 to 3), wherein R 7 and R 8 are the same or different and are independently selected from hydrogen and lower alkyl.

9. The method of claim 1 , wherein:

R 1 to R 4 are each hydrogen; and R 5 is selected from methyl, 1-(dimethylamino)-cyclopropylmethyl, 3-(dimethylamino)cyclobutyl, 1-methylazetidin-3-yl, (R)-1-methylpyrrolidin-3-yl, (S)-1-methylpyrrolidin-3-yl, and 1-methylpiperidin-4-yl, and 2-dimethylamino-ethyl.

10. The method of claim 1 , wherein the compound of formula (I) is a compound of formula (Ia):

or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:

X is O, S, or CH 2 ;

Q is C—R 10 or N

R 9 is CH 3 or CH 2 CH 2 F; and

R 10 is H or CH 3 .

11. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

12. The method of claim 1 , where the compound of formula (I) is selected from the group consisting of:

13. A method of treating a human subject having non-small cell lung carcinoma harboring an EGFR mutation, comprising a step of administering an effective amount of an EGFR tyrosine kinase inhibitor of Formula 1

or a pharmaceutically acceptable salt thereof, in combination with a synergistically effective amount of a CDK4/6 inhibitor of Formula 2

or a pharmaceutically acceptable salt thereof; wherein the synergistically effective amount formula 2 comprises approximately 6.25 to 100 mg/kg of formula 2.

14. The method claim 13 , wherein the non-small cell lung carcinoma harbors an EGFR T790M resistance mutation.

15. The method claim 13 , wherein the salt form of the inhibitor of Formula 1 is a methanesulfonate, and the salt form of the inhibitor of Formula 2 is a hydrochloride.

16. A method of treating a human subject having an EGFR-mutant cancer that has developed an acquired resistance to an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment, comprising a step of administering to the human subject an effective amount of an EGFR tyrosine kinase inhibitor of Formula 1

or a pharmaceutically acceptable salt thereof, in combination with a synergistically effective amount of a CDK4/6 inhibitor of Formula 2,

or a pharmaceutically acceptable salt thereof; wherein the synergistically effective amount formula 2 comprises approximately 6.25 to 100 mg/kg of formula 2.

17. The method of claim 16 , wherein the EGFR-mutant cancer is breast cancer.

18. The method of claim 17 , wherein the breast cancer is estrogen receptor-positive breast cancer, progesterone receptor-positive breast cancer, or HER2-positive breast cancer.

19. The method of claim 16 , wherein the EGFR-mutant cancer is bladder cancer, glioblastoma, head and neck cancer, cervical cancer, uterine cancer, colorectal cancer, gastroesophageal cancer, prostate cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, squamous cell carcinoma, or thyroid cancer.

20. A method of treating a human subject having an EGFR-mutant cancer, wherein the subject is EGFR-TKI-treatment naive, comprising a step of administering to the human subject an effective amount of an EGFR tyrosine kinase inhibitor of Formula 1

or a pharmaceutically acceptable salt thereof, with a synergistically effective amount of a CDK4/6 inhibitor of Formula 2

or a pharmaceutically acceptable salt thereof; wherein the synergistically effective amount formula 2 comprises approximately 6.25 to 100 mg/kg of formula 2.

Assignments (1)

Continuity (2)

References Cited (13)